Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.3030
+0.0129 (4.45%)
At close: Sep 18, 2026, 4:00 PM EDT
0.3100
+0.0070 (2.31%)
After-hours: Sep 18, 2026, 7:59 PM EDT
Mereo BioPharma Group Revenue
In the year 2025, Mereo BioPharma Group had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
48.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 500.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Werewolf Therapeutics | 21.00M |
| Immutep | 13.79M |
| Metagenomi Therapeutics | 13.56M |
| Apollomics | 8.84M |
| Seres Therapeutics | 1.88M |
MREO News
- 4 weeks ago - JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and ... - GuruFocus
- 4 weeks ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 4 weeks ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 5 weeks ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 5 weeks ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 5 weeks ago - Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges - GuruFocus
- 5 weeks ago - Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation ... - GuruFocus
- 5 weeks ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq